- Q1 2024 2Seventy Bio Inc Earnings Call TranscriptMay 08, 2024$4.48 (-9.68%)Earnings
- Q4 2023 2Seventy Bio Inc Earnings Call TranscriptMar 05, 2024$5.79 (+6.83%)Earnings
- 2Seventy Bio Inc Investor Call TranscriptDec 12, 2023
- Q3 2023 2Seventy Bio Inc Earnings Call TranscriptNov 14, 2023$2.28 (+0.88%)Earnings
- 2Seventy Bio Inc at Morgan Stanley Global Healthcare Conference TranscriptSep 13, 2023
- 2Seventy Bio Inc Conference Call TranscriptSep 12, 2023
- Q2 2023 2Seventy Bio Inc Earnings Call TranscriptAug 14, 2023$6.03 (+1.34%)Earnings
- 2seventy bio, Inc. Presents at Goldman Sachs 44th Annual Global Healthcare Conference, Jun-14-2023 03:20 PM TranscriptJun 14, 2023
- 2Seventy Bio Inc R&D Deep Dive Presentation (Virtual) TranscriptMay 19, 2023
- Q1 2023 2Seventy Bio Inc Earnings Call TranscriptMay 03, 2023$10.05 (-1.28%)Earnings
- Atara Biotherapeutics Inc, Cellectis SA and 2Seventy Bio Inc at Citi BioPharma Conference- Panel TranscriptSep 07, 2022
- Q2 2022 2Seventy Bio Inc Earnings Call TranscriptAug 10, 2022$17.22 (+3.11%)Earnings
- 2Seventy Bio Inc Focus on bNHL and Solid Tumor Strategy Conference Call TranscriptSep 22, 2021
- 2Seventy Bio Inc Introduction to 2seventy's Pipeline and Next-Gen Multiple Myeloma Strategy Conference Call TranscriptSep 21, 2021
Q4 2023 2Seventy Bio Inc Earnings Call Transcript
Good day, and thank you for standing by. Welcome to the 2seventy bio fourth-quarter 2023 earnings conference call. (Operator instructions)
Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker, Elizabeth Hickin, Head of Investor Relations. Please go ahead.
Thank you, operator, and good morning, everyone. Thank you for joining us.
This morning, we issued a press release on our fourth-quarter and full-year 2023 financial results. The press release can be found in the Investors and Media section of the company's website at 2seventy bio.com.
As a reminder, today's discussion will include forward-looking statements related to 2seventy bio's current plans and expectations, which are subject to certain risks and uncertainties. These forward-looking statements include statements regarding our strategic plans, timelines, and expectations with respect to sales, efficacy, and perceived therapeutic benefits of ABECMA, the timing and
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust.png)